Skip to content
Menu

Nyxoah SA NYXH

Full chart Compare
Set alert

Price alert · NYXH

All alert types
0.88 USD +0.02 (+2.48%)

As ofNov 19, 2026, 10:59 AM EST

0.8796 Day range 0.8895
0.80 52-week range 5.39
YTD
-80.77%
1 year
-80.35%

5D +0.0417 (+4.86%)

0.86000.88000.9000WedThuFriMonTue0.8999
Market cap
89.58M
Revenue (ttm)
5.08M
EPS (ttm)
-1.83
Shares out
37.43M
Forward P/E
-5.03
YTD return
-80.77%
1-year return
-80.35%
50-day average
8.73
200-day average
9.37
Volume
3.67K
Avg volume
318.91K
Open
0.8637
Previous close
0.863
Day's range
0.8796 – 0.8895
52-week range
0.80 – 5.39
Beta
0.55
Analysts
Buy
Price target
15.60 (+1663.9%)

Key statistics

Enterprise value
227.81M
Price / sales
59.68
Price / book
2.63
Revenue growth
29.70%
Free cash flow
-35.99M
Total cash
70.98M
Total debt
23.33M
Return on equity
-49.69%
Short % of float
0.32%

Fundamental scorecard

9 of 25 checks passed on NYXH’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
NYXH Revenue — quarterly 9.17M
NYXH Net income — quarterly -17.83M
NYXH EPS — quarterly -0.177

Earnings

NYXH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.46-0.55-0.09-19.57%
Aug 6, 2024Jun 1, 2024-0.45———
Aug 6, 2024Jun 1, 2024-0.45-0.46-0.01-2.22%
May 14, 2024Mar 1, 2024-0.45-0.450.000.00%
May 14, 2024Mar 1, 2024-0.45———
Mar 5, 2024Dec 1, 2023-0.41———

Upgrades / downgrades

NYXH analyst upgrades and downgrades
DateFirmActionFromTo
Dec 13, 2024HC Wainwright & Co.reitBuyBuy
Nov 5, 2024Cantor FitzgeraldreitOverweightOverweight
Oct 11, 2024HC Wainwright & Co.mainBuyBuy
Sep 30, 2024HC Wainwright & Co.reitBuyBuy
Aug 7, 2024Cantor FitzgeraldmainOverweightOverweight
Aug 7, 2024HC Wainwright & Co.reitBuyBuy

About Nyxoah SA

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Belgium
Website
nyxoah.com

News

Your note

Sign in to keep a note on NYXH — it syncs with the Stock Master app.

Institution ownership

NYXH institution ownership
Holder% heldSharesValueReported
FMR, LLC4.99%1,715,12513.72MSep 29, 2024
Blackrock Inc.3.45%1,186,0939.49MSep 29, 2024
Franklin Resources, Inc.0.85%292,5702.34MSep 29, 2024
Millennium Management Llc0.55%187,3671.50MSep 29, 2024
CVI Holdings, LLC0.53%183,5901.47MJun 29, 2024
AXA S.A.0.44%152,0001.22MSep 29, 2024

Fund ownership

NYXH fund ownership
Holder% heldSharesValueReported
Fidelity Small Cap Growth Fund1.94%667,5575.34MAug 30, 2024
BlackRock Health Sciences Term Trust1.89%648,0415.18MSep 29, 2024
Fidelity Select Portfolios - Pharmaceuticals1.39%479,0653.83MOct 30, 2024
Blackrock Funds-Health Sciences Opportunity Portfolio1.20%411,2503.29MAug 30, 2024
Fidelity Central Investment Port-International Equity Central Fd0.98%335,7002.69MSep 29, 2024
Putnam Fds Tr-Putnam Multi Cap Core Fd0.82%282,4582.26MJul 30, 2024